SEVILLE, SPAIN — Weighing in on the current debate over whether the benefits of using digoxin are worth its perceived dangers in patients with atrial fibrillation (AF) and/or heart failure (HF), new ...

Twenty men between 19 and 38 years of age (mean, 26 years) and weighing from 55.0 to 92.7 kg (mean, 73.2 kg; all within 15% of ideal body weight) completed both phases of the study. Twenty-eight ...

Please provide your email address to receive an email when new articles are posted on . Digoxin use is associated with an increased risk for mortality in patients with atrial fibrillation and/or ...

In patients with heart failure with reduced ejection fraction (HFrEF) who have an implantable cardioverter-defibrillator (ICD), the use of digoxin may increase the risk of ventricular tachyarrhythmia ...

Digoxin, originally derived from the foxglove flower, blocks the sodium/potassium ATPase pump. The mechanism by which this decreases atrioventricular (AV) conduction is not clear, butperhaps it is due ...

Wearable device data could predict New York Heart Association functional class similarly to clinical measures and six-minute walk test. HealthDay News — For patients with atrial fibrillation, digoxin ...

The heart drug digoxin could potentially be combined with existing cancer therapies to prevent the spread of tumors, an early trial suggests. But questions remain. When you purchase through links on ...

Research in mice has shown how a drug that is already used to treat heart disease can reverse obesity in mice, with no apparent side effects. The study, by scientists at the Spanish National Cancer ...

Digoxin 0.25mg/mL; soln for IV or IM inj. Lanoxin (digoxin) Injection, 500 mcg (0.5 mg) in 2 mL (250 mcg [0.25 mg] per mL); box of 10 ampules or 10 vials. Lanoxin (digoxin) Injection Pediatric, 100 ...